复发高级别胶质瘤再程放疗:生存预后因素与放射性坏死预测因素分析
该研究回顾性分析了2009至2020年间接受再程放疗的79例复发高级别胶质瘤成人患者,中位总生存期为9.9个月(95%CI 8.3-11.6)。多因素分析显示再程手术、原发治疗至首次进展间隔≥16.3个月、原发治疗至再程放疗间隔≥23.9个月及再程放疗PTV体积<112 cc与改善总生存相关;MGMT未甲基化、≥3线既往系统治疗、至再程放疗间隔<23.9个月及PTV≥112 cc与再程放疗后6个月内早期死亡相关。同步贝伐珠单抗使用及EQD2<99 Gy2是放射性坏死的独立保护因素。
要点
- 再程放疗后中位总生存期为9.9个月(95%CI 8.3-11.6)
- 再程手术、较长治疗间隔及PTV<112 cc与改善总生存相关
- 同步贝伐珠单抗及EQD2<99 Gy2降低放射性坏死风险
核心结论
- 再程放疗后观察到较好的总生存率,并识别出包括MGMT甲基化状态在内的预后因素,可辅助患者选择和临床试验设计。
- 同步使用贝伐珠单抗可减轻放射性坏死风险。
研究设计与样本
- 回顾性研究,纳入2009至2020年本机构数据库中连续接受再程放疗的复发高级别胶质瘤成人患者79例。
- 主要终点为总生存期,次要终点包括再程放疗后早期死亡(<6个月)的预后因素及放射性坏死的预测因素。
主要发现
- 再程放疗后中位总生存期为9.9个月(95%CI 8.3-11.6)。
- 多因素分析显示,进展时再程手术(HR 0.56,p=0.027)、原发治疗至首次进展间隔≥16.3个月(HR 0.61,p=0.034)、原发治疗至再程放疗间隔≥23.9个月(HR 0.35,p<0.001)及再程放疗PTV体积<112 cc(HR 0.27,p<0.001)为改善总生存的预后因素。
- MGMT未甲基化肿瘤(OR 12.4,p=0.034)、≥3线既往系统治疗(OR 29.1,p=0.022)、至再程放疗间隔<23.9个月(OR 9.0,p=0.039)及再程放疗PTV体积≥112 cc(OR 17.8,p=0.003)的患者更可能在再程放疗后6个月内死亡。
- 12个月时放射性坏死的累积发生率为11.4%(95%CI 4.3-18.5)。
- 同步贝伐珠单抗使用(HR<0.001,p<0.001)及累积等效2 Gy分次剂量(EQD2,α/β=2)<99 Gy2(HR<0.001,p<0.001)是放射性坏死的独立保护因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Recurrent high-grade glioma (rHGG) is a heterogeneous population, and the ideal patient selection for re-irradiation (re-RT) has yet to be established. This study aims to identify prognostic factors for rHGG patients treated with re-RT. METHODS: We retrospectively reviewed consecutive adults with rHGG who underwent re-RT from 2009 to 2020 from our institutional database. The primary objective was overall survival (OS). Secondary endpoints included prognostic factors for early death (< 6 months after re-RT) and predictors of radiation necrosis (RN). RESULTS: For the 79 patients identified, the median OS after re-RT was 9.9 months (95% CI 8.3-11.6). On multivariate analyses, re-resection at progression (HR 0.56, p = 0.027), interval from primary treatment to first progression ≥ 16.3 months (HR 0.61, p = 0.034), interval from primary treatment to re-RT ≥ 23.9 months (HR 0.35, p < 0.001), and re-RT PTV volume < 112 cc (HR 0.27, p < 0.001) were prognostic for improved OS. Patients who had unmethylated-MGMT tumours (OR 12.4, p = 0.034), ≥ 3 prior systemic treatment lines (OR 29.1, p = 0.022), interval to re-RT < 23.9 months (OR 9.0, p = 0.039), and re-RT PTV volume ≥ 112 cc (OR 17.8, p = 0.003) were more likely to die within 6 months of re-RT. The cumulative incidence of RN was 11.4% (95% CI 4.3-18.5) at 12 months. Concurrent bevacizumab use (HR < 0.001, p < 0.001) and cumulative equivalent dose in 2 Gy fractions (EQD2, α/β = 2) < 99 Gy2 (HR < 0.001, p < 0.001) were independent protective factors against RN. Re-RT allowed for less corticosteroid dependency. Sixty-six percent of failures after re-RT were in-field. CONCLUSION: We observe favorable OS rates following re-RT and identified prognostic factors, including methylation status, that can assist in patient selection and clinical trial design. Concurrent use of bevacizumab mitigated the risk of RN.
引用
- Moore-Palhares D, Chen H, Keith J, et al. Re-irradiation for recurrent high-grade glioma: an analysis of prognostic factors for survival and predictors of radiation necrosis. J Neurooncol. 2023. PMID: 37256526. doi:10.1007/s11060-023-04340-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。